Related Experiment Video
Updated: Dec 9, 2025
In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
Published on: December 9, 2022
Oxytocin as a Potential Adjuvant Against COVID-19 Infection
Pratibha Thakur1, Renu Shrivastava2, Vinoy K Shrivastava1
1Department of Bioscience, Endocrinology Unit, Barkatullah University, Bhopal, India.
Insights
Oxytocin may help treat COVID-19 by reducing inflammation and oxidative stress. This peptide is safe and could improve outcomes for patients experiencing acute lung injury and other severe COVID-19 complications.
Area of Science:
- Pharmacology
- Immunology
- Infectious Diseases
Background:
- Coronavirus disease (COVID-19) presents a global health emergency.
- COVID-19 pathogenesis involves inflammation, oxidative stress, immune hyperactivation, and cytokine storms.
- Complications include acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and kidney dysfunction.
Purpose of the Study:
- To summarize the potential benefits of oxytocin in mitigating COVID-19 pathogenesis.
- To explore oxytocin's protective effects against COVID-19-related complications.
Main Methods:
- Review of existing clinical studies and experimental data on oxytocin's effects.
- Analysis of oxytocin's pharmacological properties, including anti-inflammatory, antioxidant, and immunomodulatory actions.
Main Results:
- Oxytocin demonstrates anti-inflammatory, antioxidant, and immune-modulating properties.
- It shows protective effects against ALI/ARDS, nephrotoxicity, sepsis, and ischemia-reperfusion injury.
- Oxytocin's neuromodulatory effects may benefit patients with COVID-19-related stress and anxiety.
Conclusions:
- Oxytocin shows significant promise for treating COVID-19 pathogenesis.
- Its established safety profile in experimental models and humans suggests potential clinical utility.
- Oxytocin is predicted to be highly beneficial for patients with COVID-19.
Abstract:
This study summarized the benefits of oxytocin in the attenuation of coronavirus disease (COVID-19) pathogenesis. The recent outbreak of COVID-19 has become a pandemic with 7,323,761 infected patients and has created a health emergency worldwide. On the basis of the clinical study, COVID-19 shows homology with other coronavirus pathogenesis, i.e., inflammation, oxidative stress, and hyperactivation of the immune system, resulting in cytokine storm and causing acute lung infection (ALI), acute respiratory distress syndrome (ARDS), and kidney dysfunction. Oxytocin is a peptide of nine amino acids and a well-known anti-inflammatory, anti-oxidant, and immune-modulator, which is protective against ALI/ARDS, nephrotoxicity, sepsis, and ischemia- reperfusion medical condition. Oxytocin is a neuromodulator, effective for stress, anxiety, social behavior, and depression, which may be helpful for better outcomes in patients with COVID-19. Significant data show that oxytocin can be useful in the treatment of COVID-19 pathogenesis. A direct application of OT in COVID-19 is unclear; however, its use in an experimental model and humans has continuously demonstrated its safety, and its use in patients with COVID-19 is predicted to be highly beneficial.
More Related Videos
09:12Assessing Cellular Stress and Inflammation in Discrete Oxytocin-secreting Brain Nuclei in the Neonatal Rat Before and After First Colostrum Feeding
Published on: November 14, 2018
09:03Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
Related Concept Videos
01:31Neurotransmitters
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
01:18Adrenergic Agonists: Therapeutic Classification
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:28Antimicrobial Effectiveness